Sequential monitoring and characterization of circulating tumor cells (CTCs) using the epic sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics.
Roberta Ferraldeschi
No relevant relationships to disclose
Rachel Krupa
Employment or Leadership Position - Epic Sciences
Stock Ownership - Epic Sciences
Jessica Louw
Employment or Leadership Position - Epic Sciences
Stock Ownership - Epic Sciences
Eric Tucker
Employment or Leadership Position - Epic Sciences
Stock Ownership - Epic Sciences
Natalee Bales
Employment or Leadership Position - Epic Sciences
Stock Ownership - Epic Sciences
Dena Marrinucci
Employment or Leadership Position - Epic Sciences
Stock Ownership - Epic Sciences
Penelope Flohr
No relevant relationships to disclose
Ines Figueiredo
No relevant relationships to disclose
David Lorente
No relevant relationships to disclose
Ryan Dittamore
Employment or Leadership Position - Epic Sciences
Stock Ownership - Epic Sciences
Johann Sebastian De Bono
Consultant or Advisory Role - Genentech/Roche
Research Funding - Genentech; Ventana
Other Remuneration - Genentech/Roche
Gerhardt Attard
Consultant or Advisory Role - Roche/Ventana; Veridex
Research Funding - Genentech; Ventana
Other Remuneration - Roche/Ventana; Veridex